EXACT Sciences Co. (NASDAQ:EXAS) – Leerink Swann issued their Q1 2017 earnings per share estimates for shares of EXACT Sciences in a research report issued to clients and investors on Monday. Leerink Swann analyst P. Souda forecasts that the medical research company will post earnings of ($0.40) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $30.00 target price on the stock. Leerink Swann also issued estimates for EXACT Sciences’ Q2 2017 earnings at ($0.37) EPS, Q3 2017 earnings at ($0.33) EPS, Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($1.40) EPS, Q1 2018 earnings at ($0.28) EPS, Q2 2018 earnings at ($0.25) EPS, Q3 2018 earnings at ($0.21) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.93) EPS and FY2019 earnings at ($0.43) EPS.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, February 21st. The medical research company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. EXACT Sciences had a negative return on equity of 55.44% and a negative net margin of 216.45%. The firm had revenue of $35.24 million for the quarter, compared to analyst estimates of $32.53 million. During the same period in the previous year, the company posted ($0.41) earnings per share. The company’s quarterly revenue was up 144.4% compared to the same quarter last year. COPYRIGHT VIOLATION WARNING: This report was originally published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/04/21/q1-2017-earnings-estimate-for-exact-sciences-co-exas-issued-by-leerink-swann.html.
EXAS has been the topic of a number of other reports. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday, January 24th. BTIG Research reissued a “buy” rating and issued a $22.00 price objective on shares of EXACT Sciences in a research note on Sunday, January 8th. Canaccord Genuity set a $24.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a research note on Monday, January 23rd. Craig Hallum set a $26.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a research note on Tuesday, January 31st. Finally, Benchmark Co. raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $17.00 to $27.00 in a research note on Tuesday, February 21st. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.00.
EXACT Sciences (NASDAQ:EXAS) opened at 24.24 on Wednesday. The company’s 50-day moving average price is $22.25 and its 200 day moving average price is $18.46. EXACT Sciences has a 52 week low of $5.36 and a 52 week high of $24.95. The company’s market capitalization is $2.68 billion.
In related news, COO Maneesh Arora sold 5,574 shares of the business’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $21.16, for a total value of $117,945.84. Following the transaction, the chief operating officer now owns 556,339 shares in the company, valued at $11,772,133.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP D Scott Coward sold 1,543 shares of the business’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $23.74, for a total transaction of $36,630.82. Following the completion of the transaction, the senior vice president now owns 55,478 shares in the company, valued at approximately $1,317,047.72. The disclosure for this sale can be found here. In the last three months, insiders sold 47,987 shares of company stock worth $1,028,453. 5.60% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Cantab Capital Partners LLP raised its position in EXACT Sciences by 5,352.2% in the fourth quarter. Cantab Capital Partners LLP now owns 7,524 shares of the medical research company’s stock valued at $101,000 after buying an additional 7,386 shares during the last quarter. Massmutual Trust Co. FSB ADV bought a new position in shares of EXACT Sciences during the fourth quarter valued at $134,000. Intellectus Partners LLC bought a new position in shares of EXACT Sciences during the fourth quarter valued at $134,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of EXACT Sciences during the fourth quarter valued at $192,000. Finally, BlackRock Inc. raised its position in shares of EXACT Sciences by 60.4% in the third quarter. BlackRock Inc. now owns 15,316 shares of the medical research company’s stock valued at $285,000 after buying an additional 5,769 shares in the last quarter. Institutional investors and hedge funds own 86.54% of the company’s stock.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.